Study examines cancer risks after cancer diagnosis in family member

November 01, 2005

After a person is diagnosed with cancer, increased surveillance among their family members may result in the earlier detection of asymptomatic familial cancers. This phenomenon is called detection bias and may occur for a variety of cancers, according to a new study in the November 2 issue of the Journal of the National Cancer Institute.

Accurate assessments of the risk of cancer among the family members of cancer patients are essential for clinical and genetic counseling. Knowledge of these risks may also help to identify environmental and/or heritable factors that are associated with the risks of specific cancers and may lead to prevention strategies. Because a person's diagnosis of cancer may trigger the medical examination of their relatives and the subsequent identification of more cancers, detection bias may be present and the familial risks of cancer may therfore be overestimated.

Justo Lorenzo Bermejo, Ph.D., of the German Cancer Research Centre in Heidelberg, and Kari Hemminki, M.D., Ph.D., of the German Cancer Research Centre and the Karolinska Institute in Huddinge, Sweden, followed nearly 1.7 million offspring and siblings of almost 850,000 people who had been diagnosed with cancer. They compared the incidence of melanoma and cancers of the breast, cervix, colon/rectum, lung, and prostate among relatives of patients with the incidence of those cancers in the general population.

The researchers found that daughters of women with breast cancer were more likely to be diagnosed with in situ breast cancer during the year following their mother's diagnosis than they were 5 or more years later. Similarly, the offspring of people diagnosed with melanoma were more likely to be diagnosed with melanoma in the year following their parent's diagnosis than they were 5 or more years later. In addition, the risks of in situ breast cancer, in situ cervical cancer, and invasive prostate cancer in siblings decreased with time after the diagnosis of the first familial tumor.

"The most likely reason for the detection of familial cancers close in time is that the first diagnosis leads to the earlier detection of some asymptomatic tumors by increased surveillance in relatives," the authors write.

In an editorial, Marvin Zelen, Ph.D., of the Harvard School of Public Health in Boston, notes that data on familial cancer risks may also be influenced by fluctuations in family size and that controlling for this may lead to more precise analyses. "It is apparent that in counseling, care must be taken with respect to using cancer risks derived from observations on families," he writes.
-end-
Contacts:
  • Article: Julia Rautenstrauch, German Cancer Research Centre, +49 6221 42 2854, J.Rautenstrauch@dkfz-heidelberg.de
  • Editorial: Robin Herman, Harvard School of Public Health, rherman@hsph.harvard.edu

    Citations:
  • Article: Lorenzo Bermejo J, Hemminki K. Familial Risk of Cancer Shortly After Diagnosis of the First Familial Tumor. J Natl Cancer Inst 2005;97:1575-9.
  • Editorial: Zelen M. Risks of Cancer and Families. J Natl Cancer Inst 2005;97:1556-7.

    Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage. Visit the Journal online at http://jncicancerspectrum.oxfordjournals.org/.

    Journal of the National Cancer Institute

    Related Breast Cancer Articles from Brightsurf:

    Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
    The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

    Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
    New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

    Partial breast irradiation effective treatment option for low-risk breast cancer
    Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

    Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
    Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

    More clues revealed in link between normal breast changes and invasive breast cancer
    A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

    Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
    A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

    Computers equal radiologists in assessing breast density and associated breast cancer risk
    Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

    Blood test can effectively rule out breast cancer, regardless of breast density
    A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

    Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
    Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

    Young breast cancer patients undergoing breast conserving surgery see improved prognosis
    A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

    Read More: Breast Cancer News and Breast Cancer Current Events
  • Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.